MOLECULAR DOCKING AND INTERACTION OF COUMARIN DERIVATIVES AS INHIBITORS OF GROWTH FACTOR RECEPTORS

FAHIKA NAZEERULLA

doi:10.22159/ijms.2023.v11i2.47145

Authors

FAHIKA NAZEERULLA Department of Biotechnology, Ramaiah University of Applied Sciences, Bengaluru, Karnataka, India.

DOI:

https://doi.org/10.22159/ijms.2023.v11i2.47145

Keywords:

Molecular docking, vascular endothelial growth factor receptor, Human epidermal growth factor receptor, coumarin, cancer, ADMET analysis, Phytocompounds, tyrosine kinases pathway

Abstract

Objective: Cancer is the largest cause of mortality in the globe, accounting for over 10 million deaths in 2020, or roughly one in every six. Because growth factor receptors are involved in the pathophysiology of the disease in several ways, human epidermal growth factors (HER-2 and HER-3) and vascular endothelial growth factor receptors (VEGFR-2 and VEGFR-3) might be as considered therapeutic targets. Coumarins and derivatives were chosen for this study to investigate their pharmacological characteristics and therapeutic effect against the targeted proteins implicated in the pathogenesis of different cancers.

Methods: In this work, 50 coumarins and their derivatives were chosen to assess their binding affinity with the targeted proteins (HER-2, HER-3, VEGFR-2, and VEGFR-3). PyRx, a virtual tool, was utilized to perform molecular docking. The investigation was carried out computationally, with data and molecular structures of the phytocompounds and proteins derived from Indian medicinal plants, phytochemistry, and therapeutics, as well as PubChem. The protein structure was validated using a variety of tools, including Protein Data Bank sum generate and BIOVIA discovery studio software. The pharmacological assessment of the ligands was carried out using ADMET filters.

Results: According to the results of molecular docking, the ligands Glycycoumarin, Mutisifurocoumarin, Thunberginol A, Pervilleanine, Licocoumarin A, and Murrayacoumarin C had the lowest binding affinity toward the four targeted proteins.

Conclusion: Since these compounds are effective against the growth factor receptors implicated in cancer pathogenesis, they could be a suitable candidate for cancer management and suppression. However, in vitro research is still required to support these findings.

References

Ugai T, Sasamoto N, Lee HY, Ando M, Song M, Tamimi RM, et al. Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nat Rev Clin Oncol 2022;19:656-73.

Fidler MM, Gupta S, Soerjomataram I, Ferlay J, Steliarova-Foucher E, Bray F. Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: A population-based study. Lancet Oncol 2017;18:1579-89.

Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: Review of results from 37,992 patients. Cancer Metastasis Rev 2015;34:157-64.Z

Loibl S, Gianni L. HER2-positive breast cancer. Lancet 2017;389:2415-29.

Vranić S, Bešlija S, Gatalica Z. Targeting HER2 expression in cancer: New drugs and new indications. Bosn J Basic Med Sci 2021;21:1-4.

Wang SL, Zhong GX, Wang XW, Yu FQ, Weng DF, Wang XX, et al. Prognostic significance of the expression of HER family members in primary osteosarcoma. Oncol Lett 2018;16:2185-94.

Liu X, Liu S, Lyu H, Riker AI, Zhang Y, Liu B. Development of effective therapeutics targeting HER3 for cancer treatment. Biol Proced Online 2019;21:5.

Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med 2013;273:114-27.

Klasa-Mazurkiewicz D, Jarząb M, Milczek T, Lipińska B, Emerich J. Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients. Pol J Pathol 2011;62:31-40.

Su JL, Yen CJ, Chen PS, Chuang SE, Hong CC, Kuo IH, et al. The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 2007;96:541-5.

Tomeh MA, Hadianamrei R, Zhao X. A review of curcumin and its derivatives as anticancer agents. Int J Mol Sci 2019;20:1033.

Nakamura K, Shimura N, Otabe Y, Hirai-Morita A, Nakamura Y, Ono N, et al. KNApSAcK-3D: A three-dimensional structure database of plant metabolites. Plant Cell Physiol 2013;54:e4.

Sayers EW, Beck J, Bolton EE, Bourexis D, Brister JR, Canese K, et al. Database resources of the national center for biotechnology information. Nucleic Acids Res 2021;49:D10-7.

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res 2000;28:235-42.

Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: Homology modelling of protein structures and complexes. Nucleic Acids Res 2018;46:W296-303.

Panikar S, Shoba G, Arun M, Sahayarayan JJ, Nanthini AU, Chinnathambi A, et al. Essential oils as an effective alternative for the treatment of COVID-19: Molecular interaction analysis of protease (Mpro) with pharmacokinetics and toxicological properties. J Infect Public Health 2021;14:601-10.

Tam B, Sinha S, Wang SM. Combining Ramachandran plot and molecular dynamics simulation for structural-based variant classification: Using TP53 variants as model. Comput Struct Biotechnol J 2020;18:4033-9.

Laskowski RA. PDBsum: Summaries and analyses of PDB structures. Nucleic Acids Res 2001;29:221-2.

Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods Mol Biol 2015;1263:243-50.

Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, et al. ADMETlab 2.0: An integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res 2021;49:W5-14.

Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K. Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer 2004;46:11-9.

Roy PS, Saikia BJ. Cancer and cure: A critical analysis. Indian J Cancer 2016;53:441-2.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, et al. HER kinase inhibition in patients with HER2-and HER3-mutant cancers. Nature 2018;554:189-94.

Yonesaka K. HER2-/HER3-targeting antibody-drug conjugates for treating lung and colorectal cancers resistant to EGFR inhibitors. Cancers (Basel) 2021;13:1047.

Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2011;2:1097-105.

Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer 2013;13:871-82.

Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer 2011;10:12.

Muninggar L, Widjiati W, Yuliati I, Askandar B, Hartono P. Effects of curcumin on vascular endothelial growth factor expression on Rattus norvegicus cervical cancer xenograft model. Indones J Cancer 2019;12:95.

He SD, Yang XT, Yan CC, Jiang Z, Yu SH, Zhou YY, et al. Promising compounds from Murraya exotica for cancer metastasis chemoprevention. Integr Cancer Ther 2017;16:556-62.

Song X, Yin S, Zhang E, Fan L, Ye M, Zhang Y, et al. Glycycoumarin exerts anti-liver cancer activity by directly targeting T-LAK cell-originated protein kinase. Oncotarget 2016;7:65732-43.

Takeuchi K, Ito F. Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull 2011;34:1774-80.